Adicet Bio, Inc. (ACET): Nasdaq/NYSE listing notice — Adicet Bio granted 180-day Nasdaq extension; transferred to Capital Market

Adicet Bio, Inc.

Extension until April 6, 2026 to regain $1.00 minimum bid price; transferred to Nasdaq Capital Market effective Oct 9, 2025.
Company may consider reverse stock split to meet bid price requirement; if not regained, Nasdaq will issue delisting notice.
Previous 180-day compliance period ended Oct 6, 2025; extension granted Oct 7, 2025.
No immediate impact on common stock listing; ACET continues trading under symbol ACET.

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

Adicet Bio, Inc. received a nasdaq extension granted notice regarding minimum bid price (rules 5450(a)(1), 5550(a)(2), 5810(c)(3)(A)).

Exchange: nasdaq
Notice: extension granted
Deficiency: minimum bid price
Rules: 5450(a)(1), 5550(a)(2), 5810(c)(3)(A)

Exact text from the filing

October 7, 2025, the Company received a notice (the Extension Notice) from Nasdaq informing the Company that Nasdaq has granted the Company an additional 180 calendar days, or until April 6, 2026, to regain compliance with the Bid Price Requirement for continued listing on the Nasdaq Capital Market under Nasdaq Listing Rule 5550(a)(2). In connection with the Extension Notice, the listing of the Common Stock will be transferred from the Nasdaq Global Market to the Nasdaq Capital Market, effective at the opening of business on October 9, 2025. The Extension Notice has no other immediate effect o

View on SEC.gov

5 listing & compliance notices filed in the last 30 days. Browse all listing & compliance notices →

Adicet Bio, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-25-233427

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.